XSHE
300267
Market cap995mUSD
Oct 09, Last price
3.36CNY
1D
4.02%
1Q
2.13%
Jan 2017
-74.25%
IPO
53.76%
Name
Hunan Er-Kang Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hunan Er-Kang Pharmaceutical Co., Ltd is a pharmaceutical company that manufactures and sells active pharmaceutical ingredients (APIs), completed drug formulations, and pharmaceutical excipients, serving both the Chinese domestic market and international clients. Its API portfolio features substances such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's principal finished medications include sulbenicillin sodium for injection and compound liquorice tablets. For conventional pharmaceutical excipients, it provides items like pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose. Furthermore, its advanced pharmaceutical excipient offerings encompass hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate along with its related product series. The firm was established in 2003 and is headquartered in Liuyang, China.
Key people
Fangwen Shuai
Chairman of the Board · since 2015
Jishun Gu
Deputy General Manager, Secretary of the Board · since 2020
Xiangyan Shi
Deputy General Manager, Director · since 2020
Hui Wang
Deputy General Manager · since 2019
Zhengchun Zheng
Deputy General Manager · since 2025
Jiang Xiao
Chief Engineer · since 2022
Qingrong Sun
General Manager, Director · since 2022
Xun Zhao
Chief Financial Officer, Staff Elected Director · since 2025
Independent Director · since 2025
Xue Tan
Independent Director · since 2022
Yong Wu
Independent Director · since 2025
Headquarters & legal address
长沙市浏阳经济开发区康平路167号
长沙市, HN 100000
CN
长沙市, HN 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||